natgillin/translations-raw huggingface dataset:
The third study involved 135 patients with eosinophilic asthma severe enough to need regular treatment by mouth with corticosteroids (potent anti-inflammatory medicines such as prednisone and prednisolone), and the main measure of effectiveness was how much the corticosteroid dose could be reduced using Nucala for 24 weeks compared with placebo.
Treće ispitivanje uključivalo je 135 bolesnika s eozinofilnom astmom koja je dovoljno teška da zahtijeva redovito liječenje oralnim kortikosteroidima (jaki lijekovi protiv upale kao što su prednizon i prednizolon), a glavna mjera djelotvornosti bila je količina doze kortikosteroida potrebna za smanjenje primjene lijeka Nucala tijekom 24 tjedna u usporedbi s placebom.
The third study involved 296 women with metastatic disease that got worse despite treatment with other cancer medicines (including anthracyclines and taxanes) and with combinations of cancer medicines plus trastuzumab.
Treće ispitivanje obuhvatilo je 296 žena s metastatskom bolesti čije se stanje pogoršalo usprkos terapiji drugim lijekovima protiv raka (uključujući antracikline i taksane) te kombinacijama lijekova protiv raka i trastuzumaba.
The third study involved 30 patients with aHUS who had already received at least one dose of eculizumab.
Treće je ispitivanje obuhvatilo 30 bolesnika oboljelih od aHUS-a koji su već primili najmanje jednu dozu ekulizumaba.
The third study involved 416 patients with advanced renal cell carcinoma that had got worse despite treatment with certain VEGF-targeted medicines (sunitinib, sorafenib or both).
Treće je ispitivanje uključivalo 416 bolesnika s uznapredovalim karcinomom bubrežnih stanica koji se pogoršao unatoč terapiji određenim lijekovima koji djeluju na VEGF (sunitinib, sorafenib ili oboje).
The third study involved 438 patients whose blood glucose was not adequately controlled by a combination of a GLP-1 agonist (liraglutide or exenatide) and metformin with or without other diabetes medicines taken by mouth.
Treće je ispitivanje obuhvatilo 438 bolesnika čiji dijabetes nije bio primjereno kontroliran kombinacijom agonista GLP-1 (liraglutid ili eksenatid) i metformina s drugim lijekovima za liječenje dijabetesa koji se uzimaju peroralno ili bez njih.
The third study involved 59 children aged two to 12 years.
Treće je ispitivanje uključivalo 59 djece u dobi od 2 do 12 godina.
The third study involved 829 patients who had failed previous treatment including a fluoropyrimidine and irinotecan (other chemotherapy medicines).
Treće je ispitivanje obuhvatilo 829 bolesnika kod kojih prethodno liječenje, koje je uključivalo fluoropirimidin i irinotekan (druge kemoterapijske lijekove), nije bilo uspješno.
The third study showed that the immune response triggered by M-M-RVAXPRO was the same regardless of whether it was injected into a muscle or under the skin.
Treće ispitivanje pokazalo je da je imunološki odgovor koji je potaknuo M-M-RVAXPRO isti bez obzira na to je li cjepivo injektirano u mišić ili pod kožu.
The third study was done in 278 patients with genotypes 2 or 3 hepatitis C virus who could not take or did not want to have treatment with interferon.
Treće je ispitivanje provedeno na 278 bolesnika s genotipovima 2 ili 3 virusa hepatitisa C koji nisu mogli primiti terapiju interferonom ili to nisu željeli.
The Thorinane pre-filled syringes are for single dose use only; discard any unused medicinal product.
Napunjene štrcaljke Thorinanea namijenjene su samo za jednokratnu primjenu; neiskorišteni lijek bacite.
The three active ingredients in the veterinary medicine act by contact on the parasites.
Tri djelatne tvari u veterinarsko-medicinskom proizvodu djeluju u kontaktu s parazitom.
The three areas of the body recommended for injection of Relistor are: (1) your upper legs (thighs), (2) your abdomen (stomach), and (3) your upper arm (only if injecting another person).
Tri područja na tijelu se preporučuju za davanje injekcije Relistora: (1) natkoljenice (bedra), (2) abdomen (trbuh) i (3) nadlaktica (samo ako dajete injekciju drugoj osobi).
The three main metabolic routes are as follows: monohydroxylation in the dihydrobenzofuran ring; dihydrobenzofuran ring opening and
Postoje tri glavna metabolička puta: monohidroksilacija u dihidrobenzofuranskom prstenu; otvaranje dihidrobenzofuranskog prstena, i
The three most frequent non-haematological adverse reactions were dizziness (15.5%), constipation (8.2%) and herpes zoster (6.4%).
Tri najučestalije nehematološke nuspojave bile su omaglica (15,5%), konstipacija (8,2%) i herpes zoster (6,4%).
The three most frequent non-haematological laboratory abnormalities (any CTCAE grade) were hypercholesterolaemia (30.0%), raised alanine aminotransferase (22.7%) and raised aspartate aminotransferase (20.9%).
Tri najučestalije nehematološke laboratorijske abnormalnosti (bilo kojeg stupnja prema CTCAE-u) bile su hiperkolesterolemija (30,0%), povišena alanin aminotransferaza (22,7%) i povišena aspartat aminotransferaza (20,9%).
The three Phase 3 studies included one study conducted in non-cirrhotic treatment-naïve patients (ION-3); one study in cirrhotic and non-cirrhotic treatment-naïve patients (ION-1); and one study in cirrhotic and non-cirrhotic patients who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor (ION-2).
Tri ispitivanja faze 3 uključivala su jedno ispitivanje provedeno u pacijenata bez ciroze koji prethodno nisu bili liječeni (ION-3); jedno ispitivanje u pacijenata s cirozom i bez ciroze koji prethodno nisu bili liječeni (ION-1); i jedno ispitivanje u pacijenata s cirozom i bez ciroze u kojih je prethodna terapija režimom na temelju interferona bila neuspješna, uključujući režime koji su sadržavali inhibitor proteaze HCV-a (ION-2).
The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 12).
Tri preporučena mjesta za injekciju za Enbrel uključuju: (1) prednju stranu sredine natkoljenice, (2) trbuh, s iznimkom područja u krugu 5 cm oko pupka te (3) vanjsku stranu nadlaktice (vidjeti sliku 11).
The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 17).
Tri preporučena mjesta uboda za injekciju Enbrela uključuju: (1) prednju stranu sredine natkoljenice, (2) trbuh, s iznimkom područja u krugu 5 cm oko pupka te (3) vanjsku stranu nadlaktice (vidjeti sliku 17).
The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 17).
Tri preporučena mjesta za injekciju Enbrela uključuju: (1) prednju stranu sredine natkoljenice, (2) trbuh, s iznimkom područja u krugu 5 cm oko pupka te (3) vanjsku stranu nadlaktice (vidjeti sliku 17).
The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 17).
Tri preporučena mjesta za injekciju Enbrela uključuju: (1) prednju stranu sredine natkoljenice; (2) trbuh, s iznimkom područja u krugu 5 cm oko pupka; te (3) vanjsku stranu nadlaktice (vidjeti sliku 17).
The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 9).
Tri preporučena mjesta za injekciju Enbrela uključuju: (1) prednju stranu sredine natkoljenice; (2) trbuh, s iznimkom područja u krugu 5 cm oko pupka; te (3) vanjsku stranu nadlaktice (vidjeti sliku 9).
The three recommended injection sites for Enbrel include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 9).
Tri preporučena mjesta za injekciju za Enbrel uključuju: (1) prednju stranu sredine natkoljenice; (2) trbuh, s iznimkom područja u krugu 5 cm oko pupka; te (3) vanjsku stranu nadlaktice (vidjeti sliku 9).
The three strips are marked with "Week 1", "Week 2" and
Tri trake su označene sa "1. tjedan",
The three-month standard pack contains 168 x 30 mg tablets.
Standardno pakiranje za tri mjeseca liječenja sadrži 168 tableta x 30 mg.
The three-month treatment course can be repeated.
Tromjesečna serija liječenja može se ponoviti.
The threshold concentration required is dependent on the organism and the amount and type of β-lactamase produced.
Potrebna granična koncentracija ovisi o organizmu te količini i vrsti proizvedenih beta-laktamaza.
The threshold of 20 mg/l was reached for cumulative amounts of mitotane of approximately 500 g.
Prag od 20 mg/l je dostignut kod kumulativnih doza mitotana od 500 g.
The Thyrogen solution should be a clear, colourless solution.
Otopina lijeka Thyrogen mora biti bistra i bezbojna.
the thyroid gland does not work properly (thyroid disorders), too much hormone is produced (hyperthyroidism) inflammation of the pancreas (pancreatitis), see section 2 ‘Warnings and precautions’ blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome).
neispravan rad štitne žlijezde (poremećaji štitne žlijezde), proizvodi se previše hormona (hipertireoza) upala gušterače (pankreatitis), pogledajte dio 2 „Upozorenja i mjere opreza“ krvni ugrušci u malim krvnim žilama koji mogu utjecati na Vaše bubrege (trombotička trombocitopenička purpura ili hemolitički uremički sindrom).
the thyroid gland does not work properly (too little hormone is produced) (hypothyroidism)
neispravan rad štitne žlijezde (proizvodi premalo hormona) (hipotireoza)
the thyroid gland does not work properly (too little hormone is produced) (hypothyroidism),
štitna žlijezda ne funkcionira kako treba (stvara se premalo hormona) (hipotireoidizam),
the thyroid gland does not work properly(thyroid disorders), too much hormone is produced (hyperthyroidism), inflammation of the pancreas (pancreatitis), see section 2 “Warnings and precautions”, blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uraemic syndrome).
štitna žlijezda ne funkcionira pravilno (poremećaji štitnjače), stvara se previše hormona (hipertireoidizam), upala gušterače (pankreatitis), pogledajte dio 2 „Upozorenja i mjere opreza“, krvni ugrušci u malim krvnim žilama koji mogu utjecati na Vaše bubrege (trombotička trombocitopenička purpura ili hemolitički uremički sindrom).
The thyroid gland may function either excessively, or insufficiently.
Funkcija štitnjače može biti pojačana ili smanjena.
The time action profile of Levemir is statistically significantly less variable and therefore more predictable than for NPH (Neutral Protamine Hagedorn) insulin as seen from the within-subject Coefficients of Variation (CV) for the total and maximum pharmacodynamic effect in Table 1.
Profil vremenskog djelovanja lijeka Levemir statistički je značajno manje varijabilan te stoga predvidljiviji od profila NPH (Neutral Protamin Hagedorn) inzulina, što se vidi po intraindividualnim koeficijentima varijacije (CV) ukupnog i maksimalnog farmakodinamičkog učinka u Tablici 1.
The time to 10% of total INS exposure was reached earlier by approximately 5–6 min with insulin glulisine.
Vrijeme do postizanja 10% ukupne izloženosti inzulinu dosegnuto je otprilike 5-6 minuta ranije s inzulinom glulizinom.
The time to first skeletal-related event at the 25th percentile in the ZYTIGA group was twice that of the control group at 9.9 months versus 4.9 months.
Vrijeme do nastupa prvog koštanog događaja na 25. percentili u skupini liječenoj lijekom ZYTIGA bilo je dva puta dulje nego u kontrolnoj skupini - 9,9 mjeseci naspram 4,9 mjeseci.
The time to maximum concentration is, on average, half of that for biphasic human insulin 30.
Vrijeme do postizanja vršne koncentracije iznosi, u prosjeku, polovicu vremena potrebnog kod primjene bifazičnog humanog inzulina 30.
The time to pain improvement (i.e.,  2 point decrease from baseline in BPI-SF worst pain score) was similar for denosumab and zoledronic acid in each study and the integrated analyses.
Vrijeme do smanjenja osjeta boli (odnosno, ≥ 2 boda smanjenja od početne vrijednosti u rezultatu za najveću bol prema Kratkom upitniku o boli, BPI-SF) bilo je slično za denosumab i zoledronatnu kiselinu u svakom od ispitivanja i u integriranoj analizi.
The time to pain progression at the 25th percentile was 7.4 months in the ZYTIGA group, versus 4.7 months in the placebo group.
Vrijeme do progresije boli na 25. percentili bilo je 7,4 mjeseca u skupini liječenoj lijekom ZYTIGA u odnosu na 4,7 mjeseci u skupini koja je primala placebo.
The time to peak, terminal half-life and mean residence time were not affected by ketoconazole (see section 4.4).
Ketokonazol nije utjecao na vrijeme do postizanja vršnih vrijednosti, terminalni poluvijek i srednje vrijeme zadržavanja (MRT) (vidjeti dio 4.4).
The time to peak, terminal half-life and mean residence time were not affected by ketoconazole (see section 4.4).
Ketokonazol nije utjecao na vrijeme do postizanja vršnih vrijednosti, terminalni poluvijek i srednje vrijeme zadržavanja (vidjeti dio 4.4).
The time to recovery from succinylcholine-induced neuromuscular blockade (1 mg/kg) was compared with sugammadex (16 mg/kg, 3 minutes later) – induced recovery from rocuronium-induced neuromuscular blockade (1.2 mg/kg).
Vrijeme do oporavka od neuromuskularne blokade izazvane sukcinilkolinom (1 mg/kg) uspoređeno je s vremenom do oporavka od neuromuskularne blokade izazvane rokuronijem (1,2 mg/kg) nakon primjene sugamadeksa (16 mg/kg, 3 minute kasnije).
the time window if this resulted in no virologic data on treatment during the specified window. e Includes subjects who discontinued for reasons other than an adverse event, death, or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up. f Plus background regimen of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg fixed-dose combination
djelotvornosti, npr. povučeni pristanak, gubitak mogućnosti praćenja. f Plus pozadinski režim kombinacije fiksne doze emtricitabina 200 mg i tenofovirdizoproksilfumarata 300 mg
The time you eat meals and use your insulin.
rasporedu uzimanja obroka i inzulina
The timing between the removal of the biopsy and MACI implantation can vary depending on logistical factors in addition to the quality and number of cells obtained from the biopsy.
Vrijeme između uzimanja uzorka i implantacije MACI implantata može varirati ovisno o logističkim faktorima te kvaliteti i broju stanica dobivenih biopsijom.
The timing between the removal of the biopsy and the implantation of the MACI implant can vary depending on logistics and the quality and number of cells in the biopsy.
Vrijeme između uzimanja uzorka i implantacije MACI implantata može varirati ovisno o logističkim faktorima te kvaliteti i broju stanica dobivenih biopsijom.
The timing of leukapheresis: one or two leukaphereses on days 5 and 6 which is often sufficient.
Planiranje leukafereze; jedna ili dvije leukafereze 5. i 6. dan, što je često dovoljno.
The timing of ovulation cannot be predicted and therefore ellaOne should be taken as soon as possible after unprotected intercourse.
Vrijeme ovulacije nije moguće predvidjeti, stoga ellaOne treba uzeti što je prije moguće nakon nezaštićenog snošaja.
The timing of the injection is adjusted according to the dates of mating and farrowing (giving birth).
Vrijeme injekcije prilagođava se u skladu s datumima parenja i prasenja (davanja mladih).
The tiny air bubbles in the insulin reservoir that do not move with tapping will not interfere with the injection and dosage.
Mali mjehurići zraka u spremniku s inzulinom koji se ne pomiču kad kuckate po njemu neće utjecati na injekciju i dozu.
The tiny air bubbles in the insulin reservoir that do not move with tapping will not interfere with the injection and dose.
Mali mjehurići zraka u spremniku s inzulinom koji se ne pomiču kad kuckate po njemu neće utjecati na injekciju i dozu.
The tiny particles of medication in the capsule are picked up by the airflow and carried down your airway into your lungs.
Protok zraka prikuplja sitne čestice lijeka prisutne u kapsuli i dovodi ih kroz dišne puteve u pluća.
The tip cap from the Removab pre-filled syringe is removed with the tip pointing up.
Ukloni se zatvarač vrha s Removab napunjene štrcaljke pri čemu ona mora biti usmjerena vrhom prema gore.
The tmax was delayed by approximately 1 hour compared to that under fasted conditions
Vrijednost tmax bila je dosegnuta s odgodom od približno 1 sata u usporedbi s vrijednošću postignutom mjerenjem natašte.
The TOBI Podhaler Phase III clinical development programme consisted of two studies and 612 treated patients with a clinical diagnosis of CF, confirmed by quantitative pilocarpine iontophoresis sweat chloride test or well-characterised disease causing mutations in each cystic fibrosis transmembrane regulator (CFTR) gene, or abnormal nasal transepithelial potential difference characteristic of CF.
Program faze III kliničkog razvoja TOBI Podhalera sastojao se od dva ispitivanja i 612 liječenih bolesnika s kliničkom dijagnozom CF-a, potvrđenom kvantitativnom pilokarpinskom iontoforezom za određivanje klorida u znoju ili dobro karakteriziranim mutacijama koje uzrokuju bolest u svakom genu za cistično-fibrozni transmembranski regulator provodljivosti (CFTR), ili abnormalnim električnim potencijalom nosne sluznice karakterističnim za CF.
The Tolero nebuliser handset must be cleaned and disinfected as described in the instructions for use of the device.
Ručni atomizator Tolero mora se očistiti i dezinficirati kako je opisano u uputama za uporabu uređaja.
the top of the thighs
gornji dio bedra
the top of your thighs, the abdomen (see grey areas in picture 3) avoiding the skin directly surrounding the navel.
gornji dio bedara, trbuh (vidjeti siva područja na slici 3) s time da morate izbjegavati kožu neposredno oko pupka.
the top of your thighs, the abdomen (see grey areas in picture 4) avoiding the skin directly surrounding the navel.
gornji dio bedara, trbuh (vidjeti siva područja na slici 4) s time da morate izbjegavati kožu neposredno oko pupka.
the top of your thighs, the abdomen, except for the area around the navel (see grey areas in picture 5).
gornji dio bedra. trbuh, osim područja oko pupka (vidjeti siva područja na slici 5).
the top of your thighs, the abdomen, except for the area around the navel (see grey areas in picture 6).
gornji dio bedra, trbuh, osim područja oko pupka (vidjeti siva područja na slici 6).
the top of your thighs; and the abdomen, except for the area around the navel (see picture 3).
gornji dio bedara; te trbuh, osim područja oko pupka (vidjeti sliku 3).
the top of your thighs; and the abdomen, except for the area around the navel.
gornji dio bedara; i trbuh, osim područja oko pupka.
the top of your thighs; and the abdomen, except for the area around the navel.
gornji dio bedra; i trbuh, osim područja oko pupka.
The topical anaesthetic or oral analgesic should be used in accordance with the medicinal product’s instructions for use.
Topikalni anestetik ili oralni analgetik treba primijeniti u skladu s uputama za primjenu lijeka.
The topical application, with additional potential oral exposure from grooming, also results in partial systemic exposure that decreases over time.
Topička primjena s dodatnim potencijalom izloženosti preko usta (zbog dotjerivanja), dovodi do djelomične sustavne izloženosti koja se smanjuje tijekom vremena.
The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0 %.
O-glukuronida topotekana i N- desmetil O-glukuronida topotekana u urinu bilo je manje od 2,0 %.
The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0 %.
O-glukuronida topotekana i N- desmetil O-glukuronida topotekana u urinu bilo je manje od 2,0%.
The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0 %.
Topotekan-O-glukuronida i N- desmetil topotekan-O-glukuronida topotekana u urinu bilo je manje od 2,0 %.
The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0%.
O-glukuronida topotekana i N- desmetil O-glukuronida topotekana u urinu bilo je manje od 2,0 %.
The total amount of sulphur hexafluoride administered in a clinical dose is extremely small, (in a 2 ml dose the microbubbles contain 16 µl of gas).
Ukupna količina sumporovog heksafluorida primijenjenog u kliničkoj dozi je izuzetno mala, (u dozi od 2 ml mikromjehurići sadrže16 µl plina).
The total and maximum-glucose-lowering effects of Ryzodeg increase linearly with increasing doses.
Učinci lijeka Ryzodeg na snižavanje ukupne i najviše razine glukoze linearno se povećavaju povećanjem doza.
The total body and renal clearance are 157 - 176 and 3 - 3.5 ml/min, respectively.
Ukupni tjelesni klirens iznosi 157–176, a bubrežni klirens 3–3,5 ml/min.
The total body and renal clearance are 157-176 and 3-3.5 ml/min, respectively.
Ukupni tjelesni klirens iznosi 157–176, a bubrežni klirens 3–3,5 ml/min.
The total body and renal clearance are 157-176 and 3.0-3.5 ml/min, respectively.
Sveukupni tjelesni klirens iznosi 157 -176, a bubrežni 3 – 3,5 ml/min.
The total body and renal clearance are 157-176 and 3.0-3.5 ml/min, respectively.
Sveukupni tjelesni klirens iznosi 157-176, a bubrežni 3–3,5 ml/min.
The total body clearance is 5.04 ± 2.5 l/h, independent of dose, and unaffected by gender, age, race, and body weight.
Ukupni klirens iz tijela je 5,04±2,5 l/h, neovisan o dozi i na njega ne utječu spol, dob, rasa ni tjelesna težina.
The total body clearance of selexipag is 17.9 L/h.
Ukupan tjelesni klirens seleksipaga je 17,9 l/h.
The total body clearance of sildenafil is 41 l/h with a resultant terminal phase half-life of 3-5 h.
Ukupan klirens sildenafila iz tijela iznosi 41 l/h, uz posljedični poluvijek u terminalnoj fazi od 3-5 sati.
The total body clearance of sildenafil is 41 l/h with a resultant terminal phase half-life of 3-5 h.
Ukupni tjelesni klirens sildenafila iznosi 41 l/h s rezultirajućim poluvremenom u terminalnoj fazi od 3- 5 sati.
The total body clearance of vardenafil is 56 l/h with a resultant terminal half-life of approximately
Ukupni klirens iz tijela vardenafila je 56 l/h uz rezultirajuće terminalno poluvrijeme od približno
The total body clearance of vardenafil is 56 l/h with a resultant terminal half-life of approximately 4-5 hours.
Ukupni klirens iz tijela vardenafila je 56 l/h uz rezultirajuće vrijednosti poluvijeka od približno 4-5 sati.
The total clearance of iloprost is about 20 ml/kg/min, which indicates extrahepatic contribution to the metabolism of iloprost.
Ukupni klirens iloprosta iznosi oko 20 ml/kg/min, što ukazuje na izvanjetreni doprinos metabolizmu iloprosta.
The total clearance of thiotepa ranged from 11.4 to 23.2 l/h/m2.
Ukupni klirens tiotepe je u rasponu od 11,4 do 23,2 l/h/m2.
The total clearance of tocilizumab was concentration-dependent and is the sum of the linear and non-linear clearance.
Ukupni klirens tocilizumaba ovisio je o koncentraciji i bio je jednak zbroju linearnog i nelinearnog klirensa.
The total content (0.9 ml) of the pre-filled syringe should be administered as a subcutaneous injection.
Potrebno je primijeniti ukupan sadržaj (0,9 ml) napunjene štrcaljke supkutanom injekcijom.
The total content (1 mL) of the pre-filled syringe should be administered as a subcutaneous injection only.
Cjelokupan sadržaj (1 ml) napunjene štrcaljke treba primijeniti isključivo supkutanom injekcijom.
The total content of active substance in the vial provides 1 mg per ml of active substance when reconstituted as recommended (see Package Leaflet).
Ukupni sadržaj djelatne tvari u bočici iznosi 1 mg/ml djelatne tvari nakon pripreme kako je propisano (vidjeti Uputu o lijeku).
The total daily dose and twice daily administration should be maintained.
Treba nastaviti s ukupnom dnevnom dozom i primjenom dvaput dnevno.